ARTERIAL CHEMOINFUSION IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC PANCREAS CANCER
https://doi.org/10.24884/0042-4625-2016-175-5-36-40
Abstract
The chemoinfusions (310) were carried out in celiac trunk in 167 patients with non-removed pancreas cancer at the period from 2000 to 2015. Locally advanced timorous process (stage III, n=79) was revealed in 79 patients and liver metastases (stage IV, n=88) were noted in 88 cases. The celiac axis infusion by Gemcitabine (1000 mg/m²) was applied for patients and GEMOX (Gemcitabine+Oxaliplatin 75 mg/m²) has been using since 2012. Symptomatic improvement such as decrease of pain, growth of body weight was noted in majority of patients. An average lifetime, median and one-year survival consisted of 7,6 months, 5,8 months and 10%. The patients (133) were treated by 1-2 cycles and after that by course of total body chemotherapeutics. There weren’t any serious complications. Toxic manifestations of chemotherapy weren’t higher than I-II degree and they were arrested by corrective therapy in 92 patients (55%). The celiac axis infusion is safe in patients with locally advanced and inoperable pancreas cancer. Symptomatic improvement showed the most patients. The objective response to the treatment had 20% patients and performance of repeated cycles led to increase of their survival.
About the Authors
P. G. Tarazov
Russian Research Centre of Radiology and Surgical Technologies
Russian Federation
Russian Federation
A. V. Kozlov
Russian Research Centre of Radiology and Surgical Technologies
Russian Federation
Russian Federation
D. A. Granov
Russian Research Centre of Radiology and Surgical Technologies
Russian Federation
Russian Federation
A. V. Pavlovskiy
Russian Research Centre of Radiology and Surgical Technologies
Russian Federation
Russian Federation
A. A. Polikarpov
Russian Research Centre of Radiology and Surgical Technologies
Russian Federation
Russian Federation
E. V. Rozengaus
Russian Research Centre of Radiology and Surgical Technologies
Russian Federation
Russian Federation
S. A. Popov
Russian Research Centre of Radiology and Surgical Technologies
Russian Federation
Russian Federation
E. V. Vlasova
Russian Research Centre of Radiology and Surgical Technologies
Russian Federation
Russian Federation
V. E. Moiseenko
Russian Research Centre of Radiology and Surgical Technologies
Russian Federation
Russian Federation
References
1. Гранов А. М., Давыдов М. И. Интервенционная радиология в онкологии. СПб.: Фолиант, 2013. 560 с.
2. Гершанович М. Л., Бланк М. А. Осложнения противоопухолевой терапии. СПб.: Роза ветров, 2013. 376 с.
3. Патютко Ю. И., Котельников А. Г., Кудашкин Н. Е. Современные подходы к лечению больных резектабельным протоковым раком поджелудочной железы // Современное состояние диагностики и лечения опухолей панкреатодуоденальной зоны. СПб., 2015. С. 94-95.
4. Bipat S., Phoa S. S., van Delden O. M. et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma // J. Comput. Assist. Tomogr. 2005. Vol. 29. P. 438-445.
5. Cid-Arregui A., Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma // World J. Gastroenterol. 2015. Vol. 21. P. 9297-9316.
6. Davis J. L., Pandalai P. K., Ripley R. T. et al. Expanding surgical treatment of pancreatic cancer: the role of regional chemotherapy // Pancreas. 2012. Vol. 41, № 5. P. 678-684.
7. Eisenhauer E. A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) // Eur. J. Cancer. 2009. Vol. 45. P. 228-247.
8. Han G. H., Yin Z. H., Meng X. J. et al. Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma // Chin. J. Dig. Dis. 2006. Vol. 7. P. 45-48.
9. Infante J. R., Somer B. G., Park J. O. et al. A randomized, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas // Eur. J. Cancer. 2014. Vol. 50. P. 2072-2081.
10. Li H., Zeng M. S., Zhou K. R. et al. Pancreatic adenocarcinoma: signs of vascular invasion determined by multi-detector row CT // Br. J. Radiol. 2006. Vol. 79. P. 880-887.
11. Liu F., Tang Y., Sun J. et al. Regional intra-arterial vs systemic chemotherapy for advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials // PLoS One. 2012. Vol. 7, № 7. P. 40847 [PMID: 22815840 DOI: 0.1371/journal. pone.0040847].
12. Mambrini A., Sangunetti F., Pacetti P. et al. Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: result of a ten-year experience // In Vivo. 2006. № 20. P. 751-756.
13. Philip P.A. Locally advanced pancreatic cancer: Where should we go from here? // World J. Clin. Oncol. 2011. Vol. 29. P. 4066-4068.
14. Reni M., Cereda S., Rognone A. et al. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) // Cancer Chemother. Pharmacol. 2012. Vol. 69. P. 115-123.
15. Spadi R., Brusa F., Ponzetti A. et al. Current therapeutic strategies for advanced pancreatic cancer: a review for clinicians // World J. Clin. Oncol. 2016. Vol. 10. P. 27-43.
Review
For citations:
Tarazov P.G., Kozlov A.V., Granov D.A., Pavlovskiy A.V., Polikarpov A.A., Rozengaus E.V., Popov S.A., Vlasova E.V., Moiseenko V.E. ARTERIAL CHEMOINFUSION IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC PANCREAS CANCER. Grekov's Bulletin of Surgery. 2016;175(5):36-40. (In Russ.) https://doi.org/10.24884/0042-4625-2016-175-5-36-40
Views:
430
Email this article 